Assistant Professor Tufts University North Grafton, Massachusetts, United States
Disclosure(s):
Heather Gardner, DVM, PhD, DACVIM (Oncology): No financial relationships to disclose
Our understanding of the genetics of canine cancers has historically been severely limited due to a paucity of reagents and computational tools. Within the past five years, substantial improvements in the canine genome annotation, computational tools and canine-specific reagents have facilitated marked expansion of our understanding of the genetic and immune underpinnings of multiple tumor types. Concomitant with this growth is the use of genetic and genomic techniques in clinical research settings. These efforts are designed to help bridge the gap between benchtop discovery and clinical translation. This presentation will discuss how ongoing efforts in canine lymphoma and osteosarcoma are applying new technologies in clinical research settings, and the associated challenges and limitations.
Learning Objectives:
Recognize how new technologies are being applied in canine cancer research.
Be able to understand how genetic discoveries can be validated for effective translation in clinical settings.
Understand the limitations of genetic testing in clinical settings.
